A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.

Inclusion Criteria: * BMI : more than 19 ㎏/㎡, less than 27 ㎏/㎡ * Systolic blood pressure : more than 90, less than 140 (mmHg) * Diastolic blood pressure : more than 60, less than 100 (mmHg) Exclusion Criteria: * Evidence of clinically significant, severe, active, or unstable gastrointestinal, renal,hepatic, respiratory, hematological, endocrine, or cardiovascular system disease. * A history of skin disease or skin graft * Hypersensitivity to donepezil or piperidine derivatives or any of the excipients. * A known or suspected history of drug or alcohol dependency or abuse * Patients who have participated in another clinical study within 60 days. * Whole blood within 60 days, apheresis within 30 days, transfusion within 30 days * Heavy alcohol intake(more than 21 units/week) * Heavy smoker(more than 10 cigarette/day) * Abnormal clinical laboratory values which are judged clinically significant by the investigator. * Any condition that would make the patient or the caregiver, in the opinion of the investigator, unsuitable for the study.